Amryt Pharma to present at inaugural Epidermolysis Bullosa World Congress
Francesca Morgan
Company News - 2 mins
11:14, 15th January 2020

London-listed Amryt Pharma (AIM:AMYT) FOLLOW will showcase its research on Epidermolysis Bullosa (EB), a rare and untreated skin disorder at an inaugural EB World Congress held in London later this month.

Amryt’s EB research programme aims at relieving symptoms and finding a possible cure for the genetic skin disorder for which there is currently no approved treatment.

The international biopharmaceutical company will offer information on an investigational treatment for the condition, AP101, on 21 January 2020 at the EB World Congress 2020 (EB2020).

"EB2020 presents an ideal opportunity for us to share our ideas, meet new partners and galvanise our shared vision to make a real difference for people living with EB,” said Dr Joe Wiley, CEO of Amryt.

The conference, which is taking place from 19-23 January, will offer value to EB professionals, covering strategy approaches crossing research, regulatory and funding.

“Collaborating with industry partners, sponsors such as Amryt, healthcare professionals, and the EB Community gives us hope that people living with EB will have a much brighter future,” said Congress Director, Caroline Collins.

Amryt scientist, Dr Lara Cutlar, has also been invited to present a talk on non-viral gene therapy delivery mechanisms on the same day, the company explained.

On 22 January, Dr Mark Sumeray, Amryt’s Chief Medical Officer will present an outline of the research programme as part of the conference.

The group have spent over three years supporting research efforts within the EB community as well as attracting “significant investment” to their own programme, Wiley explained.

Amryt is currently conducting a phase 3 trial in EB, the EASE trial, at 55 sites across 27 countries — results are expected later this year.

Follow News & Updates from Amryt Pharma here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist